By webmin on
Phone
N/A
Email
medinfo@blueprintmedicines.com
ClinicalTrials.gov URL
https://clinicaltrials.gov/ct2/show/NCT03862885?term=avapritinib&draw=2&rank=4
Acknowledgement
5 business days
EA Page
https://www.blueprintmedicines.com/pipeline/pre-approval-access-policy/
Sponsor
Blueprint Medicines Corporation
EA Therapies for Single Patient

Investigational medicine, avapritinib (formerly known as BLU-285)
See also:  https://clinicaltrials.gov/ct2/show/NCT03862885?term=avapritinib&draw=2&rank=4

Investigational medicine, pralsetinib (formerly known as BLU-667)
See also:  https://clinicaltrials.gov/ct2/show/NCT04204928?term=pralsetinib&draw=2&rank=1

EA Policies for Single Patient

Please see our Pre-Approval Access Policy on our website

EA Policies for Disease / Category

Avapritinib: Advanced gastrointestinal stromal tumors (GIST), advanced or smoldering systemic mastocytosis (SM), or another tumor type with a mutation in exon 17 of the KIT gene or in exon 18 of the PDGFRA gene

Pralsetinib: Advanced Non-Small Cell Lung Cancer (NSCLC) or Medullary Thyroid Cancer (MTC)